Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 58


TAp73 loss favors Smad-independent TGF-β signaling that drives EMT in pancreatic ductal adenocarcinoma.

Thakur AK, Nigri J, Lac S, Leca J, Bressy C, Berthezene P, Bartholin L, Chan P, Calvo E, Iovanna JL, Vasseur S, Guillaumond F, Tomasini R.

Cell Death Differ. 2016 Aug;23(8):1358-70. doi: 10.1038/cdd.2016.18.


Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry.

Fauchier L, Greenlaw N, Ferrari R, Ford I, Fox KM, Tardif JC, Tendera M, Steg PG; CLARIFY Investigators..

PLoS One. 2015 Apr 27;10(4):e0125164. doi: 10.1371/journal.pone.0125164.


Stromal SLIT2 impacts on pancreatic cancer-associated neural remodeling.

Secq V, Leca J, Bressy C, Guillaumond F, Skrobuk P, Nigri J, Lac S, Lavaut MN, Bui TT, Thakur AK, Callizot N, Steinschneider R, Berthezene P, Dusetti N, Ouaissi M, Moutardier V, Calvo E, Bousquet C, Garcia S, Bidaut G, Vasseur S, Iovanna JL, Tomasini R.

Cell Death Dis. 2015 Jan 15;6:e1592. doi: 10.1038/cddis.2014.557.


Further characterization of HDAC and SIRT gene expression patterns in pancreatic cancer and their relation to disease outcome.

Ouaïssi M, Silvy F, Loncle C, Ferraz da Silva D, Martins Abreu C, Martinez E, Berthézene P, Cadra S, Le Treut YP, Hardwigsen J, Sastre B, Sielezneff I, Benkoel L, Delgrande J, Ouaissi A, Iovanna J, Lombardo D, Mas E.

PLoS One. 2014 Oct 2;9(9):e108520. doi: 10.1371/journal.pone.0108520.


Impact of chronic kidney disease on use of evidence-based therapy in stable coronary artery disease: a prospective analysis of 22,272 patients.

Kalra PR, García-Moll X, Zamorano J, Kalra PA, Fox KM, Ford I, Ferrari R, Tardif JC, Tendera M, Greenlaw N, Steg PG; CLARIFY Investigators..

PLoS One. 2014 Jul 22;9(7):e102335. doi: 10.1371/journal.pone.0102335.


Germline copy number variation in the YTHDC2 gene: does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma susceptibility?

Fanale D, Iovanna JL, Calvo EL, Berthezene P, Belleau P, Dagorn JC, Bronte G, Cicero G, Bazan V, Rolfo C, Santini D, Russo A.

Expert Opin Ther Targets. 2014 Aug;18(8):841-50. doi: 10.1517/14728222.2014.920324.


Neonatal screening for cystic fibrosis: comparing the performances of IRT/DNA and IRT/PAP.

Sarles J, Giorgi R, Berthézène P, Munck A, Cheillan D, Dagorn JC, Roussey M.

J Cyst Fibros. 2014 Jul;13(4):384-90. doi: 10.1016/j.jcf.2014.01.004.


Analysis of germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variations.

Fanale D, Iovanna JL, Calvo EL, Berthezene P, Belleau P, Dagorn JC, Ancona C, Catania G, D'Alia P, Galvano A, Gulotta E, Lo Dico S, Passiglia F, Bronte G, Midiri M, Lo Re G, Cicero G, Bazan V, Russo A.

Oncology. 2013;85(5):306-11. doi: 10.1159/000354737.


Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma.

Guillaumond F, Leca J, Olivares O, Lavaut MN, Vidal N, Berthezène P, Dusetti NJ, Loncle C, Calvo E, Turrini O, Iovanna JL, Tomasini R, Vasseur S.

Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3919-24. doi: 10.1073/pnas.1219555110.


TAp73 is required for macrophage-mediated innate immunity and the resolution of inflammatory responses.

Tomasini R, Secq V, Pouyet L, Thakur AK, Wilhelm M, Nigri J, Vasseur S, Berthezene P, Calvo E, Melino G, Mak TW, Iovanna JL.

Cell Death Differ. 2013 Feb;20(2):293-301. doi: 10.1038/cdd.2012.123.


Heart rate and use of beta-blockers in stable outpatients with coronary artery disease.

Steg PG, Ferrari R, Ford I, Greenlaw N, Tardif JC, Tendera M, Abergel H, Fox KM; CLARIFY Investigators..

PLoS One. 2012;7(5):e36284. doi: 10.1371/journal.pone.0036284.


Vorapaxar in the secondary prevention of atherothrombotic events.

Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA; TRA 2P–TIMI 50 Steering Committee and Investigators..

N Engl J Med. 2012 Apr 12;366(15):1404-13. doi: 10.1056/NEJMoa1200933.


Artificial neural networks for assessing the risk factors for urinary calcium stones according to gender and family history of stone.

Dussol B, Verdier JM, Goff JM, Berthezene P, Berland Y.

Scand J Urol Nephrol. 2007;41(5):414-8.


Artificial neural networks for assessing the risk of urinary calcium stone among men.

Dussol B, Verdier JM, Le Goff JM, Berthezene P, Berland Y.

Urol Res. 2006 Feb;34(1):17-25.


Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis.

Sarles J, Berthézène P, Le Louarn C, Somma C, Perini JM, Catheline M, Mirallié S, Luzet K, Roussey M, Farriaux JP, Berthelot J, Dagorn JC.

J Pediatr. 2005 Sep;147(3):302-5.


Mice with targeted disruption of p8 gene show increased sensitivity to lipopolysaccharide and DNA microarray analysis of livers reveals an aberrant gene expression response.

Vasseur S, Hoffmeister A, Garcia-Montero A, Barthet M, Saint-Michel L, Berthézène P, Fiedler F, Closa D, Dagorn JC, Iovanna JL.

BMC Gastroenterol. 2003 Sep 8;3:25.


Gene expression profiling by DNA microarray analysis in mouse embryonic fibroblasts transformed by rasV12 mutated protein and the E1A oncogene.

Vasseur S, Malicet C, Calvo EL, Labrie C, Berthezene P, Dagorn JC, Iovanna JL.

Mol Cancer. 2003 Mar 19;2:19.


Complications of endoscopic sphincterotomy: results from a single tertiary referral center.

Barthet M, Lesavre N, Desjeux A, Gasmi M, Berthezene P, Berdah S, Viviand X, Grimaud JC.

Endoscopy. 2002 Dec;34(12):991-7.


[Long-term treatment of Alzheimer's disease: followup of a cohort of 255 patients treated with lacrine for four years].

Michel BF, Estadieu MC, Gueriot C, Berthezène P, Allain H, Bongrand MC, Bonnefoy B, Bourrin JC, Chaix L, Graa K, Lejeune A, Messana M, Pras P, Ribiere J, Rihet P, Timon-David P, Tintignac A, Vincent S, Verdier JM, Gastaut JL.

Rev Neurol (Paris). 2001 Nov;157(11 Pt 1):1365-75. French.


[Risk factors for Crohn's disease relapse after treatment of intestinal stenosis].

Girodengo L, Barthet M, Desjeux A, Berdah S, Berthezene P, Bellon P, Salducci J, Grimaud JC.

Ann Chir. 2001 May;126(4):296-301. French.

Items per page

Supplemental Content

Loading ...
Support Center